Skip Navigation
Skip to contents

J Mult Scler Neuroimmunol.  2025 Jun;16(1):1-7. 10.59578/jmsni.2025.16.1.1-7.

Diagnosis and Management of Neurological Immune Related Adverse Events

Affiliations
  • 1Department of Neurology, National Cancer Center, Goyang, Korea

Abstract

As the use of immune checkpoint inhibitors (ICIs) continues to rise, particularly in combination therapies, neurological immune-related adverse events (irAEs) are expected to become more prevalent in clinical practice. These neurological irAEs are rare but often present with atypical and multifocal manifestations, potentially leading to severe neurological impairments or even mortality. Treatment generally involves discontinuation of ICIs, along with corticosteroids, intravenous immunoglobulin, and/or plasma exchange. Effective management requires early diagnosis and a multidisciplinary approach. To this end, a comprehensive understanding of neurological irAEs by clinicians is essential, and this review describes key considerations for the accurate diagnosis and treatment of neurological irAEs.

Keyword

Immune checkpoint inhibitor; Complication; Neurology; Treatment
Full Text Links
  • JMSNI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2026 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr